ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 11-13, 2008. Mr. Burns' presentation is scheduled for Tuesday, February 12, 2008 at 2:45 p.m. (local time).
Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for
cancer. MKC-1 is an oral cell-cycle regulator with activity against the
mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase
2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer
drug, is in Phase 1 studies in advanced cancers. The Company has approved
IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a
dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is
to develop and commercialize new compounds based on the Company's expertise
in angiogenesis, cell-cycle regulation and inflammation -- processes vital
to the treatment of cancer and other diseases, such as rheumatoid
arthritis. Additional information about EntreMed is available on the
Company's web site at http://www.entremed.com and in various filings with the
Securities and Exchange Commission.
Corporate Communications &
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved